US20040014810A1 - Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid - Google Patents

Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid Download PDF

Info

Publication number
US20040014810A1
US20040014810A1 US10428020 US42802003A US2004014810A1 US 20040014810 A1 US20040014810 A1 US 20040014810A1 US 10428020 US10428020 US 10428020 US 42802003 A US42802003 A US 42802003A US 2004014810 A1 US2004014810 A1 US 2004014810A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
epa
acid
preferably
treatment
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10428020
Inventor
David Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Abstract

A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.

Description

    FIELD OF THE INVENTION
  • [0001]
    The invention relates to fatty acid treatment in schizophrenia.
  • BACKGROUND
  • [0002]
    The essential fatty acids and their conversions in the body are shown in the following table.
    n-6 EFAs n-3 EFAs
    18:2n-6 18:3n-3
    Linoleic acid (LA) α-linolenic acid (ALA)
    Figure US20040014810A1-20040122-C00001
    δ-6-desaturase
    Figure US20040014810A1-20040122-C00002
    18:3n-6 18:4n-3
    γ-Linolenic acid (GLA) Stearidonic acid (SA)
    Figure US20040014810A1-20040122-C00003
    elongation
    Figure US20040014810A1-20040122-C00004
    20:3n-6 20:4n-3
    Dihomo-γ-linolenic acid Eicosatetraenoic acid
    (DGLA)
    Figure US20040014810A1-20040122-C00005
    δ-5-desaturase
    Figure US20040014810A1-20040122-C00006
    20:4n-6 20:5n-3
    Arachidonic acid (AA) Eicosapentaenoic acid (EPA)
    Figure US20040014810A1-20040122-C00007
    elongation
    Figure US20040014810A1-20040122-C00008
    22:4n-6 22:5n-3
    Adrenic acid (AdrA)
    Figure US20040014810A1-20040122-C00009
    δ-4-desaturase
    Figure US20040014810A1-20040122-C00010
    22:5n-6 Docosahexaenoic acid (DHA)
  • [0003]
    The acids, which in nature are of the all—cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. LA z,z-octadeca-9,12-dienoic acid or D[4A z,z,z,z,z,z-docosa-4,7,10,13,16,19-hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2 n-6 or 22:6 n-3, are convenient. Initials, e.g. EPA, and shortened forms of the name e.g. eicosapentaenoic acid, are used as trival names in some instances.
  • [0004]
    In previous patent applications EPA-0347856 and EPA-0599576 we have drawn attention to the action of various essential fatty acids in schizophrenia and have claimed the use of these fatty acids in treatment. We have particularly drawn attention to the low red cell levels of arachidonic acid (AA) and docosahexaenoic acid (DHA) and to the use of these fatty acids.
  • [0005]
    Present Work
  • [0006]
    We have now unexpectedly found that one particular essential fatty acid which was previously accorded only a minor role is in fact particularly effective in treatment. This is eicosapentaenoic acid (EPA; 20:5n-3) which is present in the brain in only small amounts compared to AA and DHA. However, in a trial of treatment we have found that EPA is exceptionally effective in treatment of schizophrenia. Particularly effective are preparations comprising EPA in amounts of more than 20% of the total fatty acids present (preferably the total unsaturated fatty acids present) preferably more than 40% and very preferably more than 70%.
  • [0007]
    Studies of the use of omega-3 essential fatty acids in treatment., using a mixture of DHA and EPA, have previously shown modestly beneficial effects (Mellor et al, Human Psychopharmacology 11:39-46, 1996). The preparation used contained 18% of EPA and 12% of DHA and so far as this disclosure goes the therapeutic effects could have been caused by either component or both. An analysis of the relationship between fatty acid change and schizophrenia symptoms showed that a rise in the total omega-3 content of red cell membranes was associated with a fall in schizophrenic symptoms.
  • [0008]
    We therefore decided to try to determine the relative importance of EPA and DHA in schizophrenia. A study was carried Out with 30 schizophrenia patients, most of whom had both positive and negative symptoms as shown by the positive and negative symptom scale (PANSS) and also had some evidence of tardive dyskinesia as shown by the abnormal involuntary movements scale (AIMS). Patients were randomly assigned on a double blind basis to treatment with 20 ml of a placebo emulsion, 20 ml of a 40% emulsion providing 8 g of oil containing approximately 2.0 g of EPA and 0.4 g of DHA per day (‘EPA group’), and 20 ml of an emulsion providing approximately 2.3 g of DHA and 0.5 g of EPA per day (‘DHA group’) in 8 g of oil. Patients were scored at baseline and at the end of 12 weeks of treatment. In the placebo group, 9 patients were unchanged or deteriorated on the PANSS and AIMS scores and one improved. In the DHA group, seven patients were unchanged or deteriorated and three patients improved. In contrast, in the EPA group one patient was unchanged but nine patients showed improvement. The improvement was seen in both the negative and positive symptom scores and in the AIMS score. There was therefore a broad spectrum improvement in all aspects of the schizophrenia syndrome. The DHA group was not significantly different from placebo whereas the EPA group was significantly better than both the DHA group and the placebo group (p <0.02 in both cases).
  • [0009]
    It is therefore possible to conclude that the main therapeutic effect of treatment with EFAs is attributable to the effect of EPA. The other EFAs may contribute to some degree but there can be no doubt that EPA is primarily responsible for the positive effects of treatment with omega-3 EFA preparations. We concluded that EPA should also be effective in other psychiatric disorders such as Alzheimer's disease and depression since low levels of n-3 fan, acids have been shown in the blood and/or the brain of patients with these disorders also. Two patients with severe depression not responsive to the usual anti-depressants were therefore treated with the EPA formulation as used in the schizophrenia trial. Within 4 weeks both had shown remarkable improvement in their symptoms.
  • [0010]
    While we cannot be certain of the mechanism by which EPA is working, one possibility is that it is inhibiting the enzyme, phospholipase A2. There is considerable evidence that phospholipase (PL) A2 activity is elevated in schizophrenia (Horrobin et al, Schizophrenia Research 1994; 13: 195-207). Compounds which safely inhibit PLA2 might therefore be expected to have a therapeutic effect. In in vitro studies of the effects of fatty acids on PLA activity we have found that EPA is a potent inhibitor, whereas the relatively similar fatty acid, DHA is not. This might explain why DHA did not prove effective in the clinical studies.
  • [0011]
    We have further found that another n-3 fatty acid, stearidonic acid (18:4 n-3), is as effective in inhibiting PLA2 as is EPA. EPA and SA are 20- and 18-carbon fatty acids which have in fact been shown to inhibit the activity of phospholipase A, (Finnen, Biochem Soc. Trans 1991; 19:915). In contrast, DHA is A 22-carbon fatty acid which like other 22-carbon acids does not inhibit phospholipase. This may offer an explanation for the differences between EPA and DHA since there is evidence for overactivity of phospholipase A2 in schizophrenia. We therefore propose that stearidonic acid will be effective in treating schizophrenia and the other disorders and we include its use for that purpose alone or with EPA.
  • [0012]
    The n-6 EFAs such as linoleic acid, gammalinolenic acid (GLA) dihomogammalinolenic acid (DGLA) and arachidonic acid (AA) are important in brain structure. GLA can be metabolised to DGLA and AA. We therefore tried to see whether the addition of an oil containing linoleic acid and GLA would be beneficial in two individuals who had responded to EPA. In fact their condition appeared to be less good with addition of the n-6 EFAs. It is therefore better to treat with EPA preparations in which the levels of n-6 EFAs are kept at a low level compared to the concentration of EPA. Either n-6 EFAs should be absent or if present at a ratio to EPA of not more than 1:3, preferably 1:4 or less.
  • [0013]
    In any case to ensure that the effects secured are not countered the weight ratio of SA/EPA to any DHA present is desirably not less than 3:1 by weight and desirably 4:1 or more.
  • STATEMENT OF INVENTION
  • [0014]
    The invention is set out in the claims herein but inter alia provides a pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 1:1 and is preferably 4:1 or more, or n-6 EFAs are absent. Corresponding methods of treatment, and methods of preparation of medicaments, wherein such oils as used, are also within the invention, as are corresponding treatments of depression or Alzheimer's disease or other dementias.
  • [0015]
    The EPA can be provided in any appropriate way which will elevate the levels of EPA in the blood. Mono-, di-, and tri-glycerides, mono- or di-esters, salts, cholesterol esters, amides, phospholipids, free acids or any other appropriate form may be used to deliver the EPA. Mono or diesters of EPA as specified in previous applications where the present inventor is a co-inventor (PCT/GB96/01052 and 01053), published respectively as WO96/34855 and WO96/34846 are particularly convenient forms in which the EPA may be administered. The EPA may be derived from fish or marine mammal oils, microbial oils or even from total chemical synthesis. The EPA dose used may range from 10 mg to 100 g/day, preferably 100 mg to 20 g/day and very preferably from. 500 mg to 10/day. Oral, enteral, parenteral, topical, or any other appropriate route of administration may be used. Stearidonic acid may be provided in similar doses and in similar ways, alone or with the EPA.
  • EXAMPLES
  • [0016]
    The study described above illustrates treatment according to the invention but examples of suitable formulations are as follows:-
  • [0017]
    1. Soft gelatine capsules, each containing 200 mg of EPA in the form of one of the following:
  • [0018]
    a) An oil containing 22% EPA derived from marine or microbial sources.
  • [0019]
    b) An oil containing 56% EPA derived from marine or microbial sources.
  • [0020]
    c) An oil containing 75% of EPA derived from marine or microbial sources.
  • [0021]
    d) An oil containing 95% of EPA derived from marine, microbial or synthetic sources.
  • [0022]
    e) EPA 1-3 propane diol diester.
  • [0023]
    2. Oils as in examples 1a to 1e but formulated as an emulsion for oral administration. The emulsion may contain 5 to 50% of the oil emulsified wvith emulsifying agents oknown to these skilled in the art including natural, synthetic and semi-synthetic agents such as phospholipids and galactolipids, the latter for example as described in PCT SE95/00115 published as WO95/20943.
  • [0024]
    3. Emulsions as in 2 but sterilised and appropriately formulated for intravenous administration.
  • [0025]
    4. Oils as in examples 1a to 1e. sterilised and formulated for intramuscular or sub-cutaneous injection.
  • [0026]
    5. Oils as in examples 1a to 1e formulated for topical administration using patch or other technologies known to those skilled in the art.
  • [0027]
    6-10. As Examples 1-5 except that stearidonic acid is used instead of EPA or in admixture with it e.g. half and half.

Claims (7)

  1. 1. A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia, using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent:
  2. 2. A method of treating, or a method of preparation of a medicament for treating, schizophrenia and/or tardive dyskinesia whereby EPA and/or SA is provided in the form of an oil containing more than 20% of said acid(s), preferably more than 40% and very preferably more than 70% by weight of the total (preferably total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent.
  3. 3. A pharmaceutical preparation according to claim 1, or method according to claim 2, wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1 and is preferably 4:1 or more.
  4. 4. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of depression.
  5. 5. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of Alzheimer's disease or other dementias.
  6. 6. Pharmaceutical preparation or medicament prepared as above which is suited to, or a method of treatment as above which employs, administration of 10 mg to 100 g, preferably 100 mg to 20 g, very preferably 500 mg to 10 g, EPA and/or SA daily.
  7. 7. Use of EPA and/or SA in the preparation of a medicament for the treatment of schizophrenia and/or tardive dyskinesia, or depression, or Alzheimer's disease or other dementias, in the forth set out in claim 1, for the administration of 10 mg to 100 g, preferably 100 mg to 20 g, very preferably 500 mg to 10 g, EPA and/or SA daily, with the weight ratio of SA/EPA to n-6 EFAs if present set out in claims 1 and 2 and desirably with the SA/EPA to DHA ratio set out in claim 3; and such treatment itself.
US10428020 1996-10-11 2003-05-02 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid Abandoned US20040014810A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB9621294.9 1996-10-11
GB9621294A GB9621294D0 (en) 1996-10-11 1996-10-11 Fatty acid treatment
GB9626062A GB9626062D0 (en) 1996-10-11 1996-12-16 Fatty acid treatment
GB9626062.5 1996-12-16
US09284231 US6331568B1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US09956509 US20020065319A1 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US10428020 US20040014810A1 (en) 1996-10-11 2003-05-02 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10428020 US20040014810A1 (en) 1996-10-11 2003-05-02 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09956509 Continuation US20020065319A1 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Publications (1)

Publication Number Publication Date
US20040014810A1 true true US20040014810A1 (en) 2004-01-22

Family

ID=26310221

Family Applications (5)

Application Number Title Priority Date Filing Date
US09284231 Expired - Lifetime US6331568B1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US09956739 Expired - Fee Related US6624195B2 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US09956509 Abandoned US20020065319A1 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US10428020 Abandoned US20040014810A1 (en) 1996-10-11 2003-05-02 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US10617184 Abandoned US20040048927A1 (en) 1996-10-11 2003-07-11 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09284231 Expired - Lifetime US6331568B1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US09956739 Expired - Fee Related US6624195B2 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US09956509 Abandoned US20020065319A1 (en) 1996-10-11 2001-09-18 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10617184 Abandoned US20040048927A1 (en) 1996-10-11 2003-07-11 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Country Status (10)

Country Link
US (5) US6331568B1 (en)
EP (1) EP0956013B1 (en)
JP (1) JP4151853B2 (en)
KR (2) KR20060061409A (en)
CN (1) CN1109543C (en)
CA (1) CA2268257C (en)
DE (2) DE69720787T2 (en)
DK (1) DK0956013T3 (en)
ES (1) ES2195175T3 (en)
WO (1) WO1998016216A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158361A1 (en) * 2001-11-08 2005-07-21 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20060067975A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation UV cured gel and method of making
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US20070071798A1 (en) * 2004-09-28 2007-03-29 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US20070202149A1 (en) * 2005-10-15 2007-08-30 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20080090908A1 (en) * 2003-05-14 2008-04-17 Btg International Limited Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease
US20080109017A1 (en) * 2006-11-06 2008-05-08 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080113001A1 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080206305A1 (en) * 2004-09-28 2008-08-28 Atrium Medical Corporation Implantable barrier device
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20090023807A1 (en) * 2005-03-02 2009-01-22 Btg International Limited Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters
US20090036410A1 (en) * 2004-11-25 2009-02-05 Btg International Limited Structured Phospholipids
US20090181937A1 (en) * 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090208552A1 (en) * 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20100113810A1 (en) * 2003-08-18 2010-05-06 Btg International Limited Treatment of neurodegenerative conditions
US20100233232A1 (en) * 2009-03-10 2010-09-16 Swanick Thomas M Fatty-acid based particles
US20100297196A1 (en) * 2005-03-02 2010-11-25 Btg International Limited Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6202195B1 (en) 1996-07-26 2001-03-13 Matsushita Electric Industrial Co., Ltd. Semiconductor integrated circuit layout method
ES2195175T3 (en) * 1996-10-11 2003-12-01 Scarista Ltd pharmaceutical preparation comprising eicosapentaenoic acid and / or stearidonic acid.
KR100592842B1 (en) * 1998-01-28 2006-06-26 워너-램버트 캄파니 엘엘씨 Method for Treating Alzheimer's Disease
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
FR2788437B1 (en) * 1999-01-14 2006-08-11 Inst Rech Biolog Sa New use of phospholipids of vegetable and animal nutritional therapeutic
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
KR20030096312A (en) * 2001-04-11 2003-12-24 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Fatty alcohols and fatty acid esters useful for treatment of inflammation
CA2442943A1 (en) * 2001-04-11 2002-10-24 Yeda Research And Development Co. Ltd. Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
WO2002092779A3 (en) * 2001-05-17 2003-03-13 Pilot Therapeutics Inc Method for enriching tissues in long chain polyunsaturated fatty acids
NL1019368C2 (en) 2001-11-14 2003-05-20 Nutricia Nv Preparation for enhancing receptor activity.
US8987263B2 (en) * 2002-10-10 2015-03-24 Meir Shinitzky Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (en) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション Using a combination comprising omega-3 fatty acids, a method of treating psychiatric disorders, substance abuse disorders, and other disorders
JP2007524674A (en) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション Reelin deficiency or dysfunction and a method related thereto
ES2329809T3 (en) * 2004-01-21 2009-12-01 Tiberio Bruzzese Use of highly concentrated compositions of n-3 fatty acids selected for treatment of central nervous system disorders.
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US7550286B2 (en) * 2004-11-04 2009-06-23 E. I. Du Pont De Nemours And Company Docosahexaenoic acid producing strains of Yarrowia lipolytica
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
EP1824809A4 (en) * 2004-11-19 2010-03-03 Martek Biosciences Corp Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
GB0428318D0 (en) * 2004-12-23 2005-01-26 Laxdale Ltd Treatment for severe melancholic depression
KR20080027384A (en) * 2005-07-08 2008-03-26 마텍 바이오싸이언스스 코포레이션 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
CA2634139C (en) * 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
WO2008103753A3 (en) * 2007-02-20 2008-11-27 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
EP2114155A4 (en) * 2007-02-26 2014-04-16 Yeda Res & Dev Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
JP5711968B2 (en) * 2007-10-03 2015-05-07 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company Optimal strains of Yarrowia lipolytica to produce a high eicosapentaenoic acid (YarrowiaLipolytica)
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CA2773031A1 (en) * 2008-09-09 2010-03-18 Orygen Youth Health Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
KR20140007973A (en) 2009-02-10 2014-01-20 아마린 파마, 인크. Methods of treating hypertriglyceridemia
GB0904300D0 (en) 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
CA2772378A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
US20110218243A1 (en) * 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
CN104582698A (en) 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130449A (en) * 1989-05-22 1992-07-14 Nestec S.A. Isolation of stearidonic acid from fatty acid mixtures
US5158975A (en) * 1990-05-23 1992-10-27 Nestec S.A. Use of stearidonic acid
US6603732B2 (en) * 1999-05-21 2003-08-05 Matsushita Electric Industrial Co., Ltd. Recordable optical disk

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
JP3400466B2 (en) 1991-10-28 2003-04-28 日本水産株式会社 Process for producing a high purity eicosapentaenoic acid or an ester thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
ES2195175T3 (en) * 1996-10-11 2003-12-01 Scarista Ltd pharmaceutical preparation comprising eicosapentaenoic acid and / or stearidonic acid.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130449A (en) * 1989-05-22 1992-07-14 Nestec S.A. Isolation of stearidonic acid from fatty acid mixtures
US5158975A (en) * 1990-05-23 1992-10-27 Nestec S.A. Use of stearidonic acid
US6603732B2 (en) * 1999-05-21 2003-08-05 Matsushita Electric Industrial Co., Ltd. Recordable optical disk

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158361A1 (en) * 2001-11-08 2005-07-21 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US8460693B2 (en) 2001-11-08 2013-06-11 Atrium Medical Corporation Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent
US20110184063A1 (en) * 2003-05-14 2011-07-28 Btg International Limited Treatment of neurodegenerative conditions
US7935729B2 (en) 2003-05-14 2011-05-03 Btg International Limited Use of triglyceride oils containing γ-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease
US20080090908A1 (en) * 2003-05-14 2008-04-17 Btg International Limited Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease
US20100113595A1 (en) * 2003-08-18 2010-05-06 Btg International Limited Treatment of neurodegenerative conditions
US7964641B2 (en) 2003-08-18 2011-06-21 Btg International Limited Treatment of neurodegenerative conditions
US20100113810A1 (en) * 2003-08-18 2010-05-06 Btg International Limited Treatment of neurodegenerative conditions
US8574618B2 (en) 2004-09-28 2013-11-05 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US9827352B2 (en) 2004-09-28 2017-11-28 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20070071798A1 (en) * 2004-09-28 2007-03-29 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9682175B2 (en) 2004-09-28 2017-06-20 Atrium Medical Corporation Coating material and medical device system including same
US20080206305A1 (en) * 2004-09-28 2008-08-28 Atrium Medical Corporation Implantable barrier device
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8962023B2 (en) 2004-09-28 2015-02-24 Atrium Medical Corporation UV cured gel and method of making
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090181937A1 (en) * 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090208552A1 (en) * 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060121081A1 (en) * 2004-09-28 2006-06-08 Atrium Medical Corporation Application of a coating on a medical device
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8858978B2 (en) 2004-09-28 2014-10-14 Atrium Medical Corporation Heat cured gel and method of making
US20060078586A1 (en) * 2004-09-28 2006-04-13 Atrium Medical Corporation Barrier layer
US20060067974A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Drug delivery coating for use with a stent
US20060067975A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation UV cured gel and method of making
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US8795703B2 (en) 2004-09-28 2014-08-05 Atrium Medical Corporation Stand-alone film and methods for making the same
US8722077B2 (en) 2004-09-28 2014-05-13 Atrium Medical Corporation Drug delivery coating for use with a stent
US8263102B2 (en) 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US8001922B2 (en) 2004-09-28 2011-08-23 Atrium Medical Corporation Application of a coating on a medical device
US8722132B2 (en) 2004-09-28 2014-05-13 Atrium Medical Corporation Application of a coating on a medical device
US20060110457A1 (en) * 2004-09-28 2006-05-25 Atrium Medical Corporation Heat cured gel and method of making
US20090036410A1 (en) * 2004-11-25 2009-02-05 Btg International Limited Structured Phospholipids
US20090023807A1 (en) * 2005-03-02 2009-01-22 Btg International Limited Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters
US8114903B2 (en) 2005-03-02 2012-02-14 Btg International Limited Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
US20100297196A1 (en) * 2005-03-02 2010-11-25 Btg International Limited Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US8124127B2 (en) 2005-10-15 2012-02-28 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20070202149A1 (en) * 2005-10-15 2007-08-30 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8501229B2 (en) 2005-10-15 2013-08-06 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US9220820B2 (en) 2005-10-15 2015-12-29 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8574627B2 (en) 2006-11-06 2013-11-05 Atrium Medical Corporation Coated surgical mesh
US20080113001A1 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080109017A1 (en) * 2006-11-06 2008-05-08 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080118550A1 (en) * 2006-11-06 2008-05-22 Atrium Medical Corporation Coated surgical mesh
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20100233232A1 (en) * 2009-03-10 2010-09-16 Swanick Thomas M Fatty-acid based particles
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery

Also Published As

Publication number Publication date Type
US20030045578A1 (en) 2003-03-06 application
EP0956013A1 (en) 1999-11-17 application
KR20060061409A (en) 2006-06-07 application
US20040048927A1 (en) 2004-03-11 application
KR100657642B1 (en) 2006-12-19 grant
CN1233955A (en) 1999-11-03 application
US6624195B2 (en) 2003-09-23 grant
CA2268257C (en) 2008-05-20 grant
ES2195175T3 (en) 2003-12-01 grant
WO1998016216A1 (en) 1998-04-23 application
DK956013T3 (en) grant
US6331568B1 (en) 2001-12-18 grant
DE69720787T2 (en) 2004-03-18 grant
JP2001503743A (en) 2001-03-21 application
CA2268257A1 (en) 1998-04-23 application
KR20000049016A (en) 2000-07-25 application
DK0956013T3 (en) 2003-08-04 grant
US20020065319A1 (en) 2002-05-30 application
JP4151853B2 (en) 2008-09-17 grant
CN1109543C (en) 2003-05-28 grant
DE69720787D1 (en) 2003-05-15 grant
EP0956013B1 (en) 2003-04-09 grant

Similar Documents

Publication Publication Date Title
Bittiner et al. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis
US4871768A (en) Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6689812B2 (en) Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US4526902A (en) Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
US5698594A (en) Treatment and prevention of risk factors for cardiovascular diseases
US6835750B1 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer&#39;s disease and other diseases resulting from reduced neuronal metabolism II
US4678808A (en) Rapid acting intravenous emulsions of omega-3 fatty acid esters
US4820731A (en) Parenteral dietary supplement and method of minimizing effects of infection through diet
US4309415A (en) Method and composition for treating inflammatory disorders
US20020002154A1 (en) Method and composition for treatment of inflammatory conditions
EP1157692B1 (en) Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
Calder Effects of fatty acids and dietary lipids on cells of the immune system
US20040076695A1 (en) EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
Jones et al. A dose‐response study of 13‐cis‐retinoic acid in acne vulgaris
Brzeski et al. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs
Voorhees Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses
US5380757A (en) Method of treating vulvar dystrophy and vaginal dryness
Leventhal et al. Treatment of rheumatoid arthritis with blackcurrant seed oil
US20070105954A1 (en) Formulation containing a carboxylic acid or an ester thereof
US20070104779A1 (en) Treatment with omega-3 fatty acids and products thereof
US20040247693A1 (en) Modifying the fatty acid composition of cell membranes of organs and tissues
US5709855A (en) Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5618558A (en) Fatty acid treatment
WO1999009969A1 (en) Treatment of cell-mediated immune diseases
US6667064B2 (en) Composition and method for treatment of hypertriglyceridemia